Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 177

1.

Does Toxicity Predict Efficacy? Insight Into the Mechanism of Action of Lapatinib.

Fontanella C, Lederer B, Nekljudova V, Untch M, von Minckwitz G, Loibl S.

J Clin Oncol. 2014 Sep 15. pii: JCO.2014.57.0499. [Epub ahead of print] No abstract available.

PMID:
25225430
[PubMed - as supplied by publisher]
2.

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44 - GeparQuinto).

von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B; for the GBG/AGO-B study groups.

Ann Oncol. 2014 Sep 15. pii: mdu455. [Epub ahead of print]

PMID:
25223482
[PubMed - as supplied by publisher]
3.

Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehne FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S.

Ann Oncol. 2014 Sep 11. pii: mdu450. [Epub ahead of print] Review.

PMID:
25214542
[PubMed - as supplied by publisher]
4.

PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer.

Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C.

J Clin Oncol. 2014 Sep 8. pii: JCO.2014.55.7876. [Epub ahead of print]

PMID:
25199759
[PubMed - as supplied by publisher]
5.

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.

Loibl S, Rokitta D, Conrad B, Harbeck N, Wüllner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H, Mehta K, Fuhr U, von Minckwitz G.

Breast Care (Basel). 2014 Jul;9(3):169-74. doi: 10.1159/000363430.

PMID:
25177258
[PubMed]
6.

Brightness through Local Constraint-LNA-Enhanced FIT Hybridization Probes for In Vivo Ribonucleotide Particle Tracking.

Hövelmann F, Gaspar I, Loibl S, Ermilov EA, Röder B, Wengel J, Ephrussi A, Seitz O.

Angew Chem Int Ed Engl. 2014 Aug 28. doi: 10.1002/anie.201406022. [Epub ahead of print]

PMID:
25167966
[PubMed - as supplied by publisher]
7.

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.

Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching PA, Mau C, Pantel K, Schwarzenbach H.

Breast Cancer Res Treat. 2014 Aug;147(1):61-8. doi: 10.1007/s10549-014-3079-3. Epub 2014 Aug 3.

PMID:
25086636
[PubMed - in process]
8.

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes.

Darb-Esfahani S, von Minckwitz G, Denkert C, Ataseven B, Högel B, Mehta K, Kaltenecker G, Rüdiger T, Pfitzner B, Kittel K, Fiedler B, Baumann K, Moll R, Dietel M, Eidtmann H, Thomssen C, Loibl S.

BMC Cancer. 2014 Jul 28;14:546. doi: 10.1186/1471-2407-14-546.

PMID:
25070172
[PubMed - in process]
Free PMC Article
9.

Magnetizability and rotational g tensors for density fitted local second-order Møller-Plesset perturbation theory using gauge-including atomic orbitals.

Loibl S, Schütz M.

J Chem Phys. 2014 Jul 14;141(2):024108. doi: 10.1063/1.4884959.

PMID:
25028000
[PubMed - in process]
10.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group.

N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1.

PMID:
24881463
[PubMed - indexed for MEDLINE]
11.

Surgical treatment of primary breast cancer in the neoadjuvant setting.

Kümmel S, Holtschmidt J, Loibl S.

Br J Surg. 2014 Jul;101(8):912-24. doi: 10.1002/bjs.9545. Epub 2014 May 19. Review.

PMID:
24838656
[PubMed - indexed for MEDLINE]
12.

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M.

Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30.

PMID:
24794243
[PubMed - indexed for MEDLINE]
13.

Chemotherapy for 70-Year-Old Women with Breast Cancer in Germany: A Survey by the German Breast Group.

Barinoff J, Traut A, Bauerschlag D, Bischoff J, Herr D, Lübbe K, Lück HJ, Maass N, Mundhenke C, Schmidt M, Schwedler K, Thill M, Steffen J, Loibl S, von Minckwitz G.

Geburtshilfe Frauenheilkd. 2013 May;73(5):433-439.

PMID:
24771923
[PubMed]
Free PMC Article
14.

First international consensus guidelines for breast cancer in young women (BCY1).

Partridge AH, Pagani O, Abulkhair O, Aebi S, Amant F, Azim HA Jr, Costa A, Delaloge S, Freilich G, Gentilini OD, Harbeck N, Kelly CM, Loibl S, Meirow D, Peccatori F, Kaufmann B, Cardoso F.

Breast. 2014 Jun;23(3):209-20. doi: 10.1016/j.breast.2014.03.011. Epub 2014 Apr 24.

PMID:
24767882
[PubMed - in process]
15.

Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44).

Gerber B, von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Loibl S, Untch M.

Ann Surg Oncol. 2014 Aug;21(8):2517-24. doi: 10.1245/s10434-014-3606-9. Epub 2014 Apr 18.

PMID:
24740826
[PubMed - in process]
16.

RANK expression as a prognostic and predictive marker in breast cancer.

Pfitzner BM, Branstetter D, Loibl S, Denkert C, Lederer B, Schmitt WD, Dombrowski F, Werner M, Rüdiger T, Dougall WC, von Minckwitz G.

Breast Cancer Res Treat. 2014 Jun;145(2):307-15. doi: 10.1007/s10549-014-2955-1. Epub 2014 Apr 16.

PMID:
24737168
[PubMed - in process]
17.

Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.

Reinisch M, von Minckwitz G, Harbeck N, Janni W, Kümmel S, Kaufmann M, Elling D, Nekljudova V, Loibl S.

Breast Care (Basel). 2013 Mar;8(1):60-6. doi: 10.1159/000346834.

PMID:
24715845
[PubMed]
Free PMC Article
18.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.

Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19.

PMID:
24656685
[PubMed - indexed for MEDLINE]
Free Article
19.

Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea? Reply to K.-D. Yu et al.

von Minckwitz G, Loibl S.

J Clin Oncol. 2014 Apr 20;32(12):1283-4. doi: 10.1200/JCO.2013.54.4437. Epub 2014 Mar 17. No abstract available.

PMID:
24638006
[PubMed - indexed for MEDLINE]
20.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C.

Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.

PMID:
24608200
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk